| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
|
Lancet
|
2004
|
42.12
|
|
2
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
|
N Engl J Med
|
2009
|
18.03
|
|
3
|
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
|
Lancet
|
2008
|
13.34
|
|
4
|
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
|
Circulation
|
2006
|
11.49
|
|
5
|
Apixaban in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
9.97
|
|
6
|
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).
|
Eur Heart J
|
2007
|
9.80
|
|
7
|
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
|
Eur Heart J
|
2013
|
9.54
|
|
8
|
Dronedarone in high-risk permanent atrial fibrillation.
|
N Engl J Med
|
2011
|
8.93
|
|
9
|
Long-term use of ticagrelor in patients with prior myocardial infarction.
|
N Engl J Med
|
2015
|
8.69
|
|
10
|
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.
|
Lancet
|
2011
|
8.49
|
|
11
|
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
|
JAMA
|
2004
|
7.32
|
|
12
|
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
|
Eur Heart J
|
2007
|
6.51
|
|
13
|
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).
|
J Am Coll Cardiol
|
2006
|
6.11
|
|
14
|
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006.
|
JAMA
|
2007
|
6.06
|
|
15
|
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
|
Circulation
|
2006
|
5.95
|
|
16
|
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death).
|
J Am Coll Cardiol
|
2006
|
5.81
|
|
17
|
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.
|
Eur Heart J
|
2006
|
5.79
|
|
18
|
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
|
JAMA
|
2006
|
5.74
|
|
19
|
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
|
Lancet
|
2010
|
5.30
|
|
20
|
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
|
N Engl J Med
|
2006
|
5.24
|
|
21
|
Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE).
|
Lancet
|
2002
|
4.99
|
|
22
|
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
|
N Engl J Med
|
2007
|
3.74
|
|
23
|
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
|
N Engl J Med
|
2006
|
3.56
|
|
24
|
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
|
Europace
|
2006
|
3.52
|
|
25
|
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.
|
Eur Heart J
|
2004
|
3.51
|
|
26
|
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.
|
Eur Heart J
|
2005
|
3.50
|
|
27
|
Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology.
|
Eur Heart J
|
2004
|
3.45
|
|
28
|
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
|
Europace
|
2006
|
3.11
|
|
29
|
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.
|
JAMA
|
2007
|
3.09
|
|
30
|
Darapladib for preventing ischemic events in stable coronary heart disease.
|
N Engl J Med
|
2014
|
2.90
|
|
31
|
Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry).
|
Am J Cardiol
|
2002
|
2.82
|
|
32
|
Resistance to oral antiplatelet drugs--a Position Paper of the Working Group on antiplatelet drug resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society.
|
Kardiol Pol
|
2008
|
2.63
|
|
33
|
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
|
JAMA
|
2007
|
2.57
|
|
34
|
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
|
Eur Heart J
|
2006
|
2.54
|
|
35
|
Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE).
|
Circulation
|
2004
|
2.38
|
|
36
|
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
|
Eur Heart J
|
2011
|
2.21
|
|
37
|
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events.
|
Chest
|
2004
|
2.19
|
|
38
|
Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?
|
Circulation
|
2007
|
2.12
|
|
39
|
Early and late effects of clopidogrel in patients with acute coronary syndromes.
|
Circulation
|
2003
|
2.05
|
|
40
|
Guidelines on management (diagnosis and treatment) of syncope-update 2004. Executive Summary.
|
Eur Heart J
|
2004
|
2.01
|
|
41
|
Participation in thrombolytic trials delays reperfusion therapy in acute myocardial infarction.
|
Kardiol Pol
|
2012
|
2.01
|
|
42
|
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Eur Heart J
|
2011
|
1.98
|
|
43
|
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2010
|
1.96
|
|
44
|
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE).
|
Eur Heart J
|
2003
|
1.94
|
|
45
|
Management of grown up congenital heart disease.
|
Eur Heart J
|
2003
|
1.94
|
|
46
|
A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study.
|
Eur Heart J
|
2010
|
1.90
|
|
47
|
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
|
J Am Coll Cardiol
|
2007
|
1.75
|
|
48
|
Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation.
|
J Am Coll Cardiol
|
2012
|
1.73
|
|
49
|
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
|
JAMA
|
2010
|
1.66
|
|
50
|
Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2.
|
Indian Heart J
|
2005
|
1.59
|
|
51
|
The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes.
|
Am Heart J
|
2009
|
1.57
|
|
52
|
Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events.
|
Arch Intern Med
|
2004
|
1.57
|
|
53
|
Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events).
|
JACC Cardiovasc Interv
|
2009
|
1.56
|
|
54
|
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
|
Am Heart J
|
2010
|
1.53
|
|
55
|
Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes.
|
Am Heart J
|
2007
|
1.51
|
|
56
|
Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes.
|
Am Heart J
|
2011
|
1.48
|
|
57
|
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
|
Am Heart J
|
2009
|
1.47
|
|
58
|
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
|
Eur Heart J
|
2010
|
1.45
|
|
59
|
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.
|
J Am Coll Cardiol
|
2009
|
1.43
|
|
60
|
In-hospital outcomes associated with fibrinolytic and thienopyridine use in patients with ST-segment elevation acute myocardial infarction. The global registry of acute coronary events.
|
Rev Esp Cardiol
|
2009
|
1.42
|
|
61
|
Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score.
|
Eur Heart J
|
2010
|
1.39
|
|
62
|
Efficacy and safety of closing postcatheterisation pseudoaneurysms with ultrasound-guided thrombin injections using two approaches: bolus versus slow injection. A prospective randomised trial.
|
Kardiol Pol
|
2011
|
1.38
|
|
63
|
The diagnostic and prognostic value of right ventricular myocardial velocities in inferior myocardial infarction treated with primary percutaneous intervention.
|
Kardiol Pol
|
2011
|
1.38
|
|
64
|
Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE).
|
Am Heart J
|
2004
|
1.34
|
|
65
|
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.
|
Eur Heart J
|
2004
|
1.34
|
|
66
|
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.
|
Eur Heart J
|
2009
|
1.27
|
|
67
|
Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study.
|
BMJ
|
2005
|
1.20
|
|
68
|
[ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary].
|
Rev Port Cardiol
|
2007
|
1.10
|
|
69
|
Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial.
|
JACC Cardiovasc Interv
|
2013
|
1.06
|
|
70
|
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
|
Eur Heart J
|
2009
|
1.02
|
|
71
|
Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.
|
Am J Cardiol
|
2002
|
1.02
|
|
72
|
Informed consent for clinical trials in acute coronary syndromes and stroke following the European Clinical Trials Directive: investigators' experiences and attitudes.
|
Trials
|
2008
|
0.96
|
|
73
|
Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study.
|
Eur Heart J
|
2012
|
0.95
|
|
74
|
Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events).
|
Am J Cardiol
|
2007
|
0.93
|
|
75
|
Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events.
|
Am Heart J
|
2009
|
0.92
|
|
76
|
Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
|
Eur Heart J
|
2007
|
0.92
|
|
77
|
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
|
Clin Chem
|
2011
|
0.90
|
|
78
|
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
|
Circulation
|
2008
|
0.90
|
|
79
|
The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE).
|
Am Heart J
|
2006
|
0.90
|
|
80
|
Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
|
Stroke
|
2012
|
0.88
|
|
81
|
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
|
Am Heart J
|
2007
|
0.87
|
|
82
|
Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE).
|
Am Heart J
|
2006
|
0.86
|
|
83
|
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction.
|
Am Heart J
|
2009
|
0.85
|
|
84
|
[New model of the optimal oral antiplatelet treatment in patients with the ST-segment elevation myocardial infarction in Poland. Polish Cardiac Society statement].
|
Kardiol Pol
|
2011
|
0.85
|
|
85
|
Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [GRACE]).
|
Am J Cardiol
|
2012
|
0.83
|
|
86
|
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
|
Am Heart J
|
2005
|
0.82
|
|
87
|
Long-term prognostic value of an index of myocardial performance in patients with myocardial infarction.
|
Clin Cardiol
|
2002
|
0.82
|
|
88
|
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
|
Am Heart J
|
2005
|
0.82
|
|
89
|
Differences between local hospital and core laboratory interpretation of the admission electrocardiogram in patients with acute coronary syndromes and their relation to outcome.
|
Am J Cardiol
|
2007
|
0.81
|
|
90
|
[Femoral pseudoaneurysms - ultrasound-guided thrombin injection as a method of treatment].
|
Kardiol Pol
|
2008
|
0.81
|
|
91
|
Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials.
|
Eur Heart J
|
2009
|
0.81
|
|
92
|
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study.
|
Clin Chem
|
2013
|
0.81
|
|
93
|
Right ventricular dysfunction and exercise capacity after inferior (posterior) wall acute myocardial infarction.
|
Am J Cardiol
|
2012
|
0.80
|
|
94
|
Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial).
|
Am J Cardiol
|
2011
|
0.79
|
|
95
|
[Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes].
|
Rev Port Cardiol
|
2008
|
0.79
|
|
96
|
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial.
|
Eur Heart J
|
2008
|
0.78
|
|
97
|
Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.
|
Pharmacoeconomics
|
2003
|
0.78
|
|
98
|
Can we improve the accuracy of risk assessment in patients with non ST-segment elevation acute coronary syndromes?
|
Kardiol Pol
|
2013
|
0.78
|
|
99
|
Assessment of the prognostic value of coronary angiography in patients with non-ST segment elevation myocardial infarction.
|
Kardiol Pol
|
2013
|
0.78
|
|
100
|
Patterns of use of heparins in ACS. Correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE).
|
Thromb Haemost
|
2003
|
0.77
|
|
101
|
A new-onset atrial fibrillation: the incidence of potassium and magnesium deficiency. The efficacy of intravenous potassium/magnesium supplementation in cardioversion to sinus rhythm.
|
Kardiol Pol
|
2004
|
0.76
|
|
102
|
[Troponin release following exercise test in patients with stable angina pectoris - risk factors and prognostic significance].
|
Kardiol Pol
|
2010
|
0.76
|
|
103
|
Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation.
|
Clin Cardiol
|
2003
|
0.76
|
|
104
|
Antiplatelet therapy beyond 2012: role of personalized medicine.
|
Pol Arch Med Wewn
|
2012
|
0.76
|
|
105
|
[New model of the optimal oral antiplatelet treatment in patients with the ST-segment elevation myocardial infarction in Poland - authors' reply].
|
Kardiol Pol
|
2012
|
0.75
|
|
106
|
[Genetic factors in pathogenesis of coronary artery disease in the young].
|
Kardiol Pol
|
2007
|
0.75
|
|
107
|
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
|
Am Heart J
|
2012
|
0.75
|
|
108
|
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
|
Kardiol Pol
|
2017
|
0.75
|
|
109
|
Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
|
Kardiol Pol
|
2014
|
0.75
|
|
110
|
Usefulness of quantitative versus qualitative ST-segment depression for risk stratification of non-ST elevation acute coronary syndromes in contemporary clinical practice.
|
Am J Cardiol
|
2008
|
0.75
|
|
111
|
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification.
|
Am Heart J
|
2007
|
0.75
|
|
112
|
Clopidogrel allergy successfully treated with corticosteroids without clopidogrel withdrawal.
|
Kardiol Pol
|
2016
|
0.75
|
|
113
|
[Invasive treatment of acute coronary syndrome in the Cardiology Clinic at the Center of Postgraduate Medical Education in 2002].
|
Kardiol Pol
|
2003
|
0.75
|
|
114
|
Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes.
|
Am Heart J
|
2011
|
0.75
|
|
115
|
A rare case of tricuspid valve mass in a patient with left and right ventricular dysfunction and severe ischaemic mitral regurgitation.
|
Kardiol Pol
|
2014
|
0.75
|
|
116
|
[Guidelines on the management of stable angina pectoris: executive summary].
|
G Ital Cardiol (Rome)
|
2006
|
0.75
|
|
117
|
Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes.
|
Am Heart J
|
2013
|
0.75
|
|
118
|
[Electrocardiogram with diffuse ST-segment changes--acute ischaemia or something else?].
|
Kardiol Pol
|
2006
|
0.75
|
|
119
|
Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial.
|
Eur Heart J Acute Cardiovasc Care
|
2022
|
0.75
|
|
120
|
[Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease].
|
Rev Esp Cardiol
|
2004
|
0.75
|
|
121
|
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. 2004.
|
Chest
|
2009
|
0.75
|
|
122
|
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.
|
Eur Heart J
|
2007
|
0.75
|